Calidi Biotherapeutics公司宣布,其目标是在今年年底前完成候选疗法CLD-401的监管申请提交。若进展顺利,公司计划于2027年初启动该疗法的首次人体临床试验。这一时间表标志着该公司在推进其新型生物治疗平台方面迈出了关键一步。
Calidi Biotherapeutics公司宣布,其目标是在今年年底前完成候选疗法CLD-401的监管申请提交。若进展顺利,公司计划于2027年初启动该疗法的首次人体临床试验。这一时间表标志着该公司在推进其新型生物治疗平台方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.